GlassScriptPhysician profile
Brianna C Rhue
NPI 1447482278
$72,648.42
in general payments reported to CMS, 2019-2025
28 companies · $538 in 2025
The $538 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,527 · 2020: $4,404 · 2021: $24K · 2022: $24K · 2023: $7,363 · 2024: $7,524 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $2,650 · Travel and Lodging: $1,181 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,343.75 |
| Food and Beverage | $2,649.67 |
| Travel and Lodging | $1,181.31 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $37,957.34 | 2019-2024 | Acuvue |
| Coopervision INC. | $18,473.95 | 2019-2024 | Misight Contact Lens, Clariti Contact Lens, Myday Contact Lens |
| Abb Con-Cise Optical Group LLC | $8,313.99 | 2019-2025 | Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $3,451.06 | 2019-2021 | |
| Visionary Optics LLC | $855.27 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $566.49 | 2022-2025 | Infuse, Miebo, Xiidra |
| Eyevance Pharmaceuticals LLC | $468.92 | 2019-2021 | |
| Topcon Healthcare, INC. | $333.05 | 2020-2025 | |
| Alcon Vision LLC | $330.11 | 2019-2025 | Precision 1, Total30, Tryptyr |
| Tarsus Pharmaceuticals, INC. | $309.60 | 2024-2025 | Xdemvy |
| Maculogix, INC. | $266.12 | 2019-2020 | |
| Optos, INC. | $168.98 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $125.00 | 2021 | |
| Horizon Therapeutics Plc | $120.89 | 2022 | |
| Optovue, INC. | $117.59 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $112.21 | 2020-2023 | |
| Glaukos Corporation | $106.88 | 2022-2025 | Photrexa Viscous and Photrexa |
| Dompe US, INC. | $103.51 | 2021-2024 | Oxervate |
| Lkc Technologies, INC. | $97.03 | 2024 | |
| Sun Pharmaceutical Industries INC. | $75.43 | 2020-2025 | |
| Oyster Point Pharma, INC. | $72.60 | 2022 | |
| Sight Sciences, INC. | $64.25 | 2021-2023 | Tearcare System |
| Visioneering Technologies, INC. | $46.57 | 2019 | |
| Lombart Brothers, INC. | $31.34 | 2019 | |
| Carl Zeiss Meditec, INC. | $23.33 | 2019 | |
| Shire North American Group INC | $22.06 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec USA, INC. | $15.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianna Rhue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.